ArticleJAMA neurology2020

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

Gustavo Luna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.